Engineering sperm-binding IgG antibodies for the development of an effective nonhormonal female contraception

  title={Engineering sperm-binding IgG antibodies for the development of an effective nonhormonal female contraception},
  author={Bhawana Shrestha and Alison Schaefer and Yong Zhu and Jamal Saada and Timothy M. Jacobs and Elizabeth C. Chavez and Stuart S. Omsted and Carlos A Cruz-Teran and Gabriela Baldeon Vaca and Kathleen Listiak Vincent and Thomas R. Moench and Samuel K. Lai},
  journal={Science Translational Medicine},
A panel of anti-sperm IgGs that effectively agglutinate human sperm in vitro and in sheep has been developed for nonhormonal contraception. Stopping sperm in its tracks Many women have contraindications to or are dissatisfied with hormone-based birth control. Here, Shrestha and colleagues developed a panel of sperm-binding antibodies based on an immunoglobulin against human sperm isolated from an infertile woman. By engineering the antibodies to contain additional antigen-binding fragments… 

Hexavalent sperm-binding IgG antibody released from vaginal film for development of potent on-demand nonhormonal female contraception

The engineering of a vaginal film loaded with hexavalent (i.e., 6 Fab) antisperm IgG, made using GMP manufacturing processes, that possesses significantly superior agglutination potency than the parent IgG is reported, enabling potent on-demand nonhormonal contraception via effectively agglUTinating all human sperm within minutes.

Quantifying the potential market for new contraceptive technologies : global projections of 2040 contraceptive needs and preferences

There has been a growing recognition in the UK that the statutory storage limit for frozen eggs, which currently stands at 10 years, requires a review. The UK regulator, the Human Fertilization and



Contraceptive effect of sperm-agglutinating monoclonal antibodies in rabbits.

The contraceptive efficacy of the MARS mAbs in the rabbit suggests that human sperm-agglutinating mAbs may be effective agents for vaginal contraception in humans.

Human Sperm-Specific Peptide Vaccine That Causes Long-Term Reversible Contraception1

The sperm-specific YLP12 peptide sequence is an attractive candidate for contraceptive vaccine and affected fertility at the prefertilization stage by inhibiting sperm capacitation and the acrosome reaction, and sperm-oocyte binding.

Fully effective contraception in male and female guinea pigs immunized with the sperm protein PH-20

100% effective contraception was obtained in male and female guinea pigs immunized with PH-20, and the contraceptive effect was long-lasting and reversible: immunized females, mated at intervals of six to fifteen months after immunization, progressively regained fertility.

Analysis of a Human Sperm CD52 Glycoform in Primates: Identification of an Animal Model for Immunocontraceptive Vaccine Development1

Analysis of the appearance of the S19 carbohydrate epitope in nonhuman primates indicates that the distinctive carbohydrate moiety of human sperm CD52 is present in the chimpanzee, and it is identified as the most appropriate primate model to study the potential of this unique CD52 glycoform as a contraceptive immunogen.

Vaccine for contraception targeting sperm

  • R. Naz
  • Biology
    Immunological reviews
  • 1999
Development of a vaccine based on sperm antigens represents a promising approach to contraception and the exciting findings from the recent trial in immunoinfertile couples indicate that the FA‐1 antigen may have clinical application in the treatment of male infertility.

A male genital tract-specific carbohydrate epitope on human CD52: implications for immunocontraception.

The S19 epitope was shown to be absent from human lymphocytes, demonstrating a distinction between this epitope and the CAMPATH epitope that is recognized by an antibody against the terminal tripeptide and GPI-anchor of CD52, and the suitability of the S19 mAb as an intravaginal contraceptive.

Analysis of Recombinant Human Semenogelin as an Inhibitor of Human Sperm Motility1

Recombinant semenogelin significantly inhibited sperm progressive motility in a dose- and time-dependent manner and Cysteine 239 of rSEMG1 appears to be the critical amino acid for both binding to eppin and inhibiting sperm motility.

Ability of spermatozoa to bind to the zona pellucida during oligozoospermia induced with testosterone during a male contraceptive trial.

To determine the ability of spermatozoa to bind to the zona pellucida (ZP) in testosterone-induced oligozoospermia, previously fertile men participating in the World Heath Organization (WHO) male

Anti-sperm antibodies and immune subfertility.

In male patients this can be achieved by direct mixed anti-globulin reaction test or immunobead-binding test on the patients' spermatozoa, and in female patients cervical mucus can be tested by indirect versions of the same tests.

Contraceptive Efficacy of a Novel Spermicidal Microbicide Used With a Diaphragm: A Randomized Controlled Trial

An acid buffering gel used with a diaphragm is a safe, acceptable contraceptive with efficacy comparable to that of a common commercial spermicide with diaphrate, and safety and acceptability were similar between the two groups.